Related Experiment Videos
Selective estrogen receptor modulators (SERMS) and their roles in breast cancer prevention
Woo-Chan Park1, V Craig Jordan
1Lynn Sage Breast Cancer Research Program, Robert H. Lurie Comprehensive Cancer Center, Olson Pavilion 8258, 303 E. Chicago Avenue, Chicago, IL 60611, USA.
Abstract:
Tamoxifen has not only proved to be a valuable treatment for estrogen receptor (ER)-positive breast cancer, but is also a pioneering medicine for chemoprevention in high-risk pre- and postmenopausal women. Insights into the pharmacology and toxicology of tamoxifen have led to the recognition of selective ER modulators (SERMs) with estrogen-like actions in maintaining bone density and in lowering circulating cholesterol, but antiestrogenic actions in the breast. Raloxifene, a related SERM, is now available to treat osteoporosis and is also being tested as a preventive for breast cancer and coronary heart disease. Emerging knowledge about the action of SERMs will provide clues for the design of mechanism-based medicines.
Insights
Selective estrogen receptor modulators (SERMs) like tamoxifen offer benefits for breast cancer treatment and prevention. These drugs show estrogen-like effects on bone and cholesterol but antiestrogenic effects on breast tissue.
Area of Science:
- Endocrinology
- Pharmacology
- Oncology
Background:
- Tamoxifen is a key treatment for estrogen receptor-positive breast cancer.
- Tamoxifen serves as a chemoprevention agent for high-risk women.
- Understanding tamoxifen's effects led to the development of selective estrogen receptor modulators (SERMs).
Purpose of the Study:
- To review the pharmacological and toxicological insights into tamoxifen.
- To discuss the role of SERMs in managing bone density and cholesterol.
- To highlight the antiestrogenic actions of SERMs in breast tissue.
- To introduce Raloxifene as a related SERM for osteoporosis and potential cancer/heart disease prevention.
Main Methods:
- Review of existing literature on tamoxifen and SERMs.
- Analysis of pharmacological and toxicological data.
- Discussion of clinical applications and ongoing research.
Main Results:
- SERMs exhibit dual actions: estrogen-like effects on bone and cholesterol, and antiestrogenic effects on breast tissue.
- Raloxifene, a SERM, is approved for osteoporosis and investigated for breast cancer and coronary heart disease prevention.
- Emerging knowledge on SERM mechanisms provides a basis for future drug design.
Conclusions:
- SERMs represent a significant advancement in managing hormone-related conditions.
- The distinct actions of SERMs offer therapeutic potential across various diseases.
- Further research into SERM mechanisms will drive the development of novel, mechanism-based medicines.